Lars Henrik Fugger

Immunomodulation in multiple sclerosis: promises and pitfalls

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperReviewResearchpeer-review

  • Calliope A Dendrou, Nuffield Department of Medicine, The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • ,
  • Lars Fugger

Multiple sclerosis (MS) afflicts about 2.5 million people globally and poses a major personal and socioeconomic burden. The recognition of MS as an inflammatory disease, characterized by infiltration of immune cells into the central nervous system, has spurred research into the autoimmune etiology of the condition and has provided the rationale for its treatment through immunomodulation. Experience with immunotherapies in MS to date has suggested a disparity between the observed immune cell infiltration and the progressive loss of neurons. However, recent clinical efforts are providing new insights into progressive MS that once again place the immune system at center stage. This article reviews the main mechanisms of MS immunopathogenesis, and the benefits, risks and challenges of immunomodulatory treatments for the disease.

Original languageEnglish
JournalCurrent Opinion in Immunology
Pages (from-to)37-43
Number of pages7
Publication statusPublished - 2017

    Research areas

  • Journal Article, Review

See relations at Aarhus University Citationformats

ID: 119030214